CA3116560A1 - Exosome-targeting bispecific antibodies - Google Patents

Exosome-targeting bispecific antibodies Download PDF

Info

Publication number
CA3116560A1
CA3116560A1 CA3116560A CA3116560A CA3116560A1 CA 3116560 A1 CA3116560 A1 CA 3116560A1 CA 3116560 A CA3116560 A CA 3116560A CA 3116560 A CA3116560 A CA 3116560A CA 3116560 A1 CA3116560 A1 CA 3116560A1
Authority
CA
Canada
Prior art keywords
seq
bispecific antibody
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3116560A
Other languages
English (en)
French (fr)
Inventor
Matthew K. Robinson
Michael John MORIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunome Inc
Original Assignee
Immunome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome Inc filed Critical Immunome Inc
Publication of CA3116560A1 publication Critical patent/CA3116560A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3116560A 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies Pending CA3116560A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746862P 2018-10-17 2018-10-17
US62/746,862 2018-10-17
PCT/US2019/056698 WO2020081786A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Publications (1)

Publication Number Publication Date
CA3116560A1 true CA3116560A1 (en) 2020-04-23

Family

ID=70284767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3116560A Pending CA3116560A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Country Status (12)

Country Link
US (1) US20210347895A1 (https=)
EP (1) EP3866851A4 (https=)
JP (2) JP7496818B2 (https=)
KR (1) KR20210091714A (https=)
CN (1) CN113423425A (https=)
AU (1) AU2019359877A1 (https=)
BR (1) BR112021007469A2 (https=)
CA (1) CA3116560A1 (https=)
IL (1) IL282355A (https=)
MX (1) MX2021004036A (https=)
SG (1) SG11202103812RA (https=)
WO (1) WO2020081786A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501062A (ja) 2018-10-02 2022-01-06 イムノーム、インコーポレイテッド Ｅｐｎ１を標的とする抗体
CN113754771A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×egfr的双特异性抗体
CN114354913B (zh) * 2021-12-31 2024-07-19 厦门大学 一种外泌体pd-l1糖基化检测方法
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
WO2023225613A2 (en) * 2022-05-18 2023-11-23 Immunome, Inc. Combination anti-epn1 and anti-pd-l1 antibody therapies
EP4630966A2 (en) * 2022-12-09 2025-10-15 The Regents of the University of California Intelligent design and engineering of proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP4141032B1 (en) * 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
RU2018105846A (ru) * 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
PT3433273T (pt) * 2016-03-25 2022-02-21 Biomunex Pharmaceuticals Moléculas de ligação a cd38 e pd-l1
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质

Also Published As

Publication number Publication date
CN113423425A (zh) 2021-09-21
AU2019359877A1 (en) 2021-05-20
JP7496818B2 (ja) 2024-06-07
EP3866851A1 (en) 2021-08-25
US20210347895A1 (en) 2021-11-11
EP3866851A4 (en) 2022-11-02
IL282355A (en) 2021-05-31
KR20210091714A (ko) 2021-07-22
JP2024123004A (ja) 2024-09-10
SG11202103812RA (en) 2021-05-28
BR112021007469A2 (pt) 2021-08-10
WO2020081786A1 (en) 2020-04-23
JP2022512734A (ja) 2022-02-07
MX2021004036A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
JP7578938B2 (ja) Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用
JP7496818B2 (ja) エキソソーム標的化二重特異性抗体
CN112512581B (zh) 针对cldn18.2和cd3的抗体构建体
CN110582297B (zh) 包含T细胞接合抗体构建体的低pH药物组合物
AU2018295119B2 (en) Multi-specific antibodies and methods of making and using thereof
BR112019022751A2 (pt) composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
BR112019021411A2 (pt) métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
EA039594B1 (ru) Биспецифические конструкции антител к bcma и cd3, вовлекающие т-клетки
CN105263961A (zh) 用于预防、诊断或者治疗癌症或血管发生相关疾病的抗vegf抗体和含有所述抗体的药物组合物
ES2800674T3 (es) Polipéptidos biespecíficos de unión a antígeno
EP3820895A1 (en) Efficiently expressed egfr and pd-l1 bispecific binding proteins
WO2022111476A1 (zh) 抗PD-L1-抗VEGF-抗TGF-β多特异性抗体、其药物组合物及用途
KR20210110818A (ko) Rank 길항제 및 이에 대한 용도
WO2022068894A1 (zh) 同时靶向pd-l1和vegf的双功能分子及其医药用途
JP2025531328A (ja) キメラ抗原受容体ｔ細胞の可逆的制御
JP2025527160A (ja) 多重特異性抗体およびその使用
WO2022127066A9 (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
KR102956517B1 (ko) 트랜스타이레틴 면역글로불린 융합
HK40060740A (en) Exosome-targeting bispecific antibodies
HK40123044B (zh) 药物组合及用途
TW202613175A (zh) Cdh3結合蛋白及其用途
TW202417488A (zh) 雙特異性抗體
AU2024341649A1 (en) Pharmaceutical combination and use
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
HK40119204A (zh) 双特异性抗体

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250829

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260417